Last reviewed · How we verify
Palmoplantar pustulosis
Approved treatments
- Tremfya · Johnson & Johnson
Guselkumab binds to IL-23's p19 subunit, blocking its interaction with the IL-23 receptor and inhibiting proinflammatory cytokine release.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Palmoplantar pustulosis patent landscape — cliff calendar, originator estates, attackable patents
- Palmoplantar pustulosis treatment landscape brief
- Palmoplantar pustulosis treatment updates RSS
Frequently asked questions about Palmoplantar pustulosis
What drugs treat Palmoplantar pustulosis?
Tracked treatments include Tremfya.
What is the treatment for Palmoplantar pustulosis?
Standard treatment for Palmoplantar pustulosis includes Tremfya. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Palmoplantar pustulosis patent cliff · Palmoplantar pustulosis CI report
- Treatment: Tremfya · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing